Single-Cell Genomics in Neurodegeneration

Introduction

Single Cell Genomics In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Single-cell genomics encompasses a suite of high-throughput technologies that profile the transcriptome, epigenome, proteome, or multi-omic state of individual cells, enabling unprecedented resolution into the cellular heterogeneity that underlies neurodegenerative . The human brain contains hundreds of distinct cell types — neurons, astrocytes, microglia platforms such as 10x Genomics Chromium, single-cell studies have generated comprehensive atlases of the healthy and diseased brain. In the context of neurodegenerative , these technologies have identified [disease-associated [microglia (DAM, revealed selective neuronal vulnerability patterns, uncovered novel astrocytes reactive states, mapped oligodendrocytes lineage disruption, and defined cell-type-specific transcriptional programs altered in alzheimers, parkinsons, als, ftd, and multiple-sclerosis (Mathys et al., 2019). ^{1Single-cell multiregion dissection of Alzheimer's disease.2024 · Nature · DOI 10.1038/s41586-024-07606-7 · PMID 39048816Open reference}

Core Technologies

Single-Cell RNA Sequencing (scRNA-seq)

scRNA-seq captures the full transcriptional state of individual cells through: ^{2A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.2017 · Cell · DOI 10.1016/j.cell.2017.05.018 · PMID 28602351Open reference}

1. Cell isolation: Tissue dissociation followed by droplet-based encapsulation (10x Genomics, inDrop), plate-based sorting (SMART-seq2), or combinatorial indexing (sci-RNA-seq)

2. Barcoding: Each cell receives a unique molecular barcode and unique molecular identifiers (UMIs) for transcript counting

3. Library preparation: Reverse transcription, amplification, and sequencing library generation

4. Sequencing and analysis: High-throughput sequencing followed by computational demultiplexing, normalization, dimensionality reduction, and clustering

Droplet-based platforms (10x Chromium) typically capture 3’-end transcripts from 5,000-20,000 cells per run at moderate depth (~2,000-5,000 genes per cell), while plate-based methods (SMART-seq2) provide full-length transcript coverage at higher depth from fewer cells, enabling isoform and splicing analysis. ^{3Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis.2021 · Nature neuroscience · DOI 10.1038/s41593-021-00862-0 · PMID 34031600Open reference}

Single-Nucleus RNA Sequencing (snRNA-seq)

For brain tissue, single-nucleus RNA sequencing (snRNA-seq) is often preferred because: ^{4Shared and distinct transcriptomic cell types across neocortical areas2018 · Nature · DOI 10.1038/s41586-018-0654-5 · PMID 30382198Open reference}

• Frozen tissue compatibility: Nuclei can be isolated from archived frozen brain tissue, enabling analysis of postmortem human brain samples critical for studying neurodegenerative

• Reduced dissociation artifacts: Enzymatic dissociation required for scRNA-seq can activate stress-responsive gene programs and selectively damage certain cell types; nuclear isolation avoids these artifacts

• Large neuron capture: Large projection neurons that are difficult to capture intact in droplets are readily profiled via their nuclei

The trade-off is reduced sensitivity (nuclear transcriptomes capture ~50-70% of the genes detected in whole-cell preparations) and loss of cytoplasmic RNA species, including mitochondrial transcripts relevant to mitochondrial-dysfunction research (Bakken et al., 2018). ^{5Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases.2020 · Nature genetics · DOI 10.1038/s41588-020-00721-x · PMID 33106633Open reference}

Single-Cell ATAC Sequencing (scATAC-seq)

scATAC-seq profiles chromatin accessibility at single-cell resolution, revealing: ^{6Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease.2020 · Nature communications · DOI 10.1038/s41467-020-19737-2 · PMID 33257666Open reference}

• Cell-type-specific regulatory element usage (enhancers, promoters)

• Transcription factor binding site accessibility changes in disease

• Epigenomic alterations in neurodegeneration beyond transcriptional changes

• Gene regulatory network inference when integrated with scRNA-seq data

This is particularly relevant for understanding how genetic risk variants for alzheimers — the majority of which fall in non-coding regulatory regions — exert their effects in specific cell types (Corces et al., 2020.

Multi-Omic Single-Cell Approaches

Cutting-edge multi-omic methods simultaneously measure multiple modalities from the same cell: ^{7Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.2022 · JAMA oncology · DOI 10.1001/jamaoncol.2021.6987 · PMID 34967848Open reference}

• SHARE-seq / 10x Multiome: Joint RNA + chromatin accessibility profiling

• CITE-seq: Surface protein detection + transcriptome from the same cell

• scNMT-seq: Nucleosome occupancy, methylation, and transcription

• Perturb-seq / CROP-seq: CRISPR perturbation + transcriptome readout for functional genomics

These integrated approaches are especially powerful for dissecting the multi-layered molecular changes occurring in neurodegenerative disease cells. ^{8Integrated multimodal cell atlas of Alzheimer’s disease2024 · Nature Neuroscience · DOI 10.1038/s41593-024-01774-5 · PMID 39402379Open reference}

Major Discoveries in Neurodegeneration

Disease-Associated Microglia (DAM)

One of the most impactful discoveries from single-cell genomics in neurodegeneration was the identification of [disease-associated microglia (DAM — a unique [microglial state found in the vicinity of amyloid-beta plaques in alzheimers mouse models and human brain tissue. DAM are characterized by upregulation of trem2, ApoE, Lpl, and phagocytic genes, with downregulation of homeostatic microglial markers (P2RY12, TMEM119, CX3CR1. [This discovery established that [microglia specific disease-response programs rather than simply being “activated” or “resting” (Keren-Shaul et al., 2017. ^{9Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease.2020 · Nature · DOI 10.1038/s41586-019-1895-7 · PMID 31915375Open reference}

Subsequent studies identified additional microglial states including interferon-responsive microglia/entities/microglia. ^{10Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.2024 · Cell · DOI 10.1016/j.cell.2023.12.004 · PMID 38181741Open reference}

Reactive Astrocyte States

scRNA-seq revealed that astrocytes in neurodegeneration adopt multiple reactive states beyond the classical A1/A2 dichotomy, including disease-associated astrocytes (DAA) characterized by glial-fibrillary-acidic-protein upregulation, loss of homeostatic functions, and gain of inflammatory and complement signaling. These states differ across brain regions and disease stages.

Oligodendrocyte Lineage Alterations

Studies in multiple-sclerosis and alzheimers revealed disruption of oligodendrocytes maturation trajectories, with accumulation of disease-specific intermediate states that fail to fully myelinate or support axons, contributing to demyelination and white matter degeneration.

CSF and Blood Cell Atlases

Single-cell profiling of cerebrospinal fluid (CSF) and peripheral blood from patients with neurodegenerative diseases has identified disease-associated immune cell populations — including expanded clonal T cells, activated monocyte subsets, and aberrant B cell populations — providing liquid biopsy biomarkers and insights into peripheral-immune-infiltration in neurodegeneration.

Computational Methods

Dimensionality Reduction and Clustering

Standard analysis pipelines employ:

• PCA for initial dimensionality reduction

• UMAP/t-SNE for visualization

• Graph-based clustering (Leiden, Louvain) for cell type identification

• Marker gene-based annotation using curated reference atlases

Cell Type Annotation

Automated annotation tools (CellTypist, scArches, Azimuth) map query datasets to reference brain cell atlases, enabling consistent cell type labeling across studies. The Allen Brain Cell Atlas and the Human Cell Atlas Brain initiative provide comprehensive reference datasets.

Trajectory Analysis and RNA Velocity

Pseudotime analysis and RNA velocity (scVelo) infer cell state transitions and differentiation trajectories from snapshot data, revealing how cells transition from healthy to disease states — for example, tracking [microglial transition or oligodendrocytes progenitor-to-myelinating cell trajectories.

Integration and Harmonization

Methods such as Harmony, scVI, and SCVI-tools enable integration of datasets across studies, laboratories, and technologies, building comprehensive meta-atlases that increase statistical power for detecting rare cell states and subtle disease effects.

Genetic Risk Variant Interpretation

Integration of scRNA-seq/scATAC-seq with genome-wide association study (GWAS data using tools like LDSC-SEG, scDRS, and SEISMIC enables cell-type-specific interpretation of genetic risk for alzheimers, parkinsons, and other neurodegenerative conditions, identifying which cell types mediate genetic risk.

Resources and Databases

Key databases for single-cell neurodegeneration research include:

• ssREAD: Single-cell and spatial RNA-seq database for Alzheimer’s Disease with 1,053 samples from 67 studies encompassing over 7.3 million cells (ssREAD, 2024

• Allen Brain Cell Atlas: Comprehensive multi-modal atlas of mouse and human brain cell types using MERFISH, scRNA-seq, and electrophysiology

• SEA-AD (Seattle Alzheimer’s Disease Brain Cell Atlas): Multi-omic atlas of the aged and AD human brain

• Human Cell Atlas Brain: International effort to map all brain cell types across development and aging

Challenges and Future Directions

Technical Limitations

• Tissue quality: Postmortem brain tissue quality varies; RNA degradation and agonal state affect transcriptomic profiles

• Dissociation bias: Certain cell types (large neurons, heavily myelinated cells) may be underrepresented

• Depth vs. throughput trade-off: Current platforms sacrifice either gene detection sensitivity or cell numbers

• Cost: Large-scale, multi-region, multi-donor studies remain expensive

Emerging Approaches

• In situ sequencing: Technologies like MERFISH, seqFISH+, and STARmap enable spatial-transcriptomics with single-cell resolution in intact tissue

• Long-read single-cell sequencing: Pacific Biosciences and Oxford Nanopore platforms enable full-length transcript isoform detection at single-cell level

• Temporal profiling: Live single-cell sequencing approaches (Live-seq) enable longitudinal tracking of individual cells over time

• Perturbation screens: Pooled CRISPR screens with single-cell readouts (Perturb-seq) in brain organoids enable functional genomics at scale

Clinical Translation

Single-cell genomics data are being translated into:

• Biomarker discovery through identification of cell-type-specific secreted proteins detectable in CSF or blood

• Drug target identification by pinpointing disease-driving molecular programs in vulnerable cell types

• Clinical trial design through patient stratification based on cellular and molecular subtypes of disease

See Also

• Apolipoprotein E (APOE - [Microglia - brain-organoids

• spatial-transcriptomics

Background

The study of Single Cell Genomics In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Mermaid Diagram: Cholinergic Basal Forebrain Pathway

flowchart TD
    A["NBM Cholinergic Neurons"]  -->|"ACh"| B["Cortex"]
    A  -->|"ACh"| C["Hippocampus"]
    B  -->  D["Cognitive Function<br/>Attention"]
    C  -->  E["Memory Formation<br/>Consolidation"]
    
    F["AD Pathology"]  -->|"Cholinergic Loss"| G["Basal Forebrain Degeneration"]
    G  -->  H["Reduced ACh"]
    H  -->  I["Memory Impairment"]
    H  -->  J["Attention Deficits"]
    
    K["Anti-Cholinergic Drugs"]  -->|"Block ACh"| L["Cognitive Decline"]
    
    style A fill:#0a1929
    style F fill:#3b1114
    style G fill:#5c1515
    style I fill:#5c1515